Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial.
We investigated the influence of 2 weeks of treatment with deprenyl on the acute effect of a single dose of 200 mg of L-dopa in a double-blind cross-over placebo-controlled trial in 16 parkinsonian patients with wearing-off phenomena. Deprenyl induced no significant benefit in the duration or the maximal improvement of L-dopa's effect. Moreover, deprenyl treatment did not improve the patient's motor status.
D000368:Aged; D000818:Animals; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010627:Phenethylamines / Q000008:administration & dosage*; D010919:Placebos; D012642:Selegiline / Q000008:administration & dosage* / Q000627:therapeutic use
D010627:Phenethylamines; D010919:Placebos; D012642:Selegiline; D007980:Levodopa